ストックスクリーナーアプリを入手
0.2158
4.55%
-0.0042
Palatin Technologies Inc. (PTN) 最新ニュース
Palatin’s obesity study shows promise in appetite control By Investing.com - Investing.com Canada
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - The Malaysian Reserve
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin (PTN) Reports Positive Phase 2 Study Results for Obesity Treatment | PTN Stock News - GuruFocus
Palatin’s obesity study shows promise in appetite control - Investing.com Australia
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide | PTN Stock News - GuruFocus
Breakthrough Obesity Treatment Shows 71% Appetite Control, Blocks Post-Treatment Weight Rebound - Stock Titan
What Analysts Think About Palatin Technologies Inc (AMEX: PTN)’s Potential Raise - stocksregister.com
Palatin Appeals NYSE American Notice of Delisting - Kilgore News Herald
Palatin Technologies (PTN) Appeals NYSE Delisting Decision | PTN Stock News - GuruFocus
Palatin Appeals NYSE American Notice of Delisting | PTN Stock Ne - GuruFocus
Palatin Appeals NYSE Delisting, Pursues Financing And Partnerships To Regain Compliance - Nasdaq
Palatin contests NYSE American delisting notice By Investing.com - Investing.com South Africa
Palatin Appeals NYSE American Notice of Delisting | PTN Stock News - GuruFocus
Palatin contests NYSE American delisting notice - Investing.com
Palatin Appeals NYSE American Notice Of Delisting - marketscreener.com
Stock Slump: Eyewear Innovator And Tech Firms Face Market Hits - Finimize
Palatin Technologies (PTN) Faces NYSE American Delisting Proceedings - GuruFocus
Palatin (PTN) Faces Delisting Proceedings from NYSE American | P - GuruFocus
Palatin to Present Positive Phase 2b Data for Melanocortin Agoni - GuruFocus
Palatin Technologies faces potential NYSE American delisting By Investing.com - Investing.com Canada
Palatin reports promising kidney disease treatment results By Investing.com - Investing.com South Africa
Palatin Technologies shares fall as it receives NYSE American delisting notice - MSN
Palatin Technologies faces potential NYSE American delisting - Investing.com Australia
Palatin Technologies, Inc. Announces Receipt Of NYSE American Notice Of Delisting And Intention To Appeal - marketscreener.com
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - PR Newswire
Palatin reports promising kidney disease treatment results - Investing.com Australia
Palatin Technologies Reports Positive Data From Phase 2b BREAKOUT Study - Nasdaq
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting - Kilgore News Herald
Indo-Asian News Service - Indo-Asian News Service (IANS)
Breakthrough: New Drug Shows 71% Success Rate in Diabetic Kidney Disease Trial - Stock Titan
Palatin Technologies stock hits 52-week low at $0.45 - Investing.com
Palatin Technologies stock hits 52-week low at $0.45 By Investing.com - Investing.com India
Palatin touts Phase II obesity study results - The Pharma Letter
Palatin study shows weight loss with new drug combo By Investing.com - Investing.com Canada
Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN) - Barchart.com
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight - Benzinga
Palatin study shows weight loss with new drug combo - Investing.com
Breakthrough Obesity Treatment: New Drug Combo Achieves 4.4% Weight Loss in Clinical Trial - Stock Titan
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - The Malaysian Reserve
Palatin reported promising results in trial for ulcerative colitis treatment - MSN
PTN stock touches 52-week low at $0.67 amid market challenges - Investing.com Australia
PTN stock touches 52-week low at $0.67 amid market challenges By Investing.com - Investing.com South Africa
Palatin’s UC therapy prompts clinical remission in a third of patients - Yahoo
Palatin Technologies' Ulcerative Colitis Drug Candidate Shows Positive Results in Phase 2 Study - MarketScreener
Palatin reported promising results in trial for ulcerative colitis treatment (PTN:NYSE) - Seeking Alpha
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - The Malaysian Reserve
0.77%
0.11%
大文字化:
|
ボリューム (24 時間):